Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
Apple Should Climb The Wall Of Worry
April 20, 2024
Microsoft Q3 Preview: Focusing On Copilot
April 19, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
OGN Stock News and Mentions of Organon & Co. Stocktwits
Updated: April 23, 2024 (10:18)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Organon Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Organon & Co. (OGN).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Organon stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Organon & Co. (OGN)
April 22, 2024 (22:15) / "Zacks Commentary" (by Zacks Equity Research)
Organon ( OGN ) Beats Stock Market Upswing: What Investors Need to Know
In the closing of the recent trading day, Organon (OGN) stood at $18, denoting a +1.01% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
April 17, 2024 (20:21) / "CNN" (by Meg Tirrell)
'Kids need to breathe just like adults do:' $35 price caps don't apply to asthma meds young children need, doctors say
'Kids need to breathe just like adults do': $35 price caps don't apply to asthma meds young children need, doctors say ...
In Article Trend: Neutral
April 16, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should WisdomTree U.S. SmallCap Dividend ETF ( DES ) Be on Your Investing Radar?
Style Box ETF report for DES ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (22:15) / "Zacks Commentary" (by Zacks Equity Research)
Organon ( OGN ) Advances While Market Declines: Some Information for Investors
In the latest trading session, Organon (OGN) closed at $17.71, marking a +1.49% move from the previous day.
In Article Trend: Neutral
April 12, 2024 (16:52) / "Benzinga" (by Zacks)
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks - IBM ( NYSE:IBM ) , Iron Mountain ( NYSE:IRM )
The S&P 500 notched a marvelous rally in the first three months of 2024, banking on AI optimism and hopes that the Federal Reserve will cut interest rates in the second half of this year. However, the broader index has experienced a topsy-turvy ride so far this month.
In Article Trend: Somewhat-Bullish
April 12, 2024 (16:37) / "Zacks Commentary" (by Zacks Equity Research)
Molina ( MOH ) Wins Deal to Serve Michigan's Medicaid Members
Molina Healthcare (MOH) wins a Medicaid contract from the MDHHS to better care for the healthcare needs of Michigan's Medicaid beneficiaries and therefore, gain more customers.
In Article Trend: Somewhat-Bullish
April 12, 2024 (12:09) / "Zacks Commentary" (by Tirthankar Chakraborty)
Play Safe! S&P 500 is Teasingly Close to its 50 DMA: 3 Picks
With the S&P 500 trading close to its 50-day moving average, it's wise for investors to place bets on safe stocks such as Iron Mountain (IRM), Organon (OGN), and International Business Machines (IBM).
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:42) / "Business Insider"
Is WisdomTree U.S. High Yield Corporate Bond ETF ( WFHY ) a Strong ETF Right Now?
Is WisdomTree U.S. High Yield Corporate Bond ETF (WFHY) a Strong ETF Right Now? - Markets Insider ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:20) / "Benzinga" (by Zacks)
Is WisdomTree U.S. High Yield Corporate Bond ETF ( WFHY ) a Strong ETF Right Now? - iShares iBoxx $ High Yield Corporate Bond ETF ( ARCA:HYG ) , Crescent Energy ( NYSE:CRGY )
Launched on 04/27/2016, the WisdomTree U.S. High Yield Corporate Bond ETF WFHY is a smart beta exchange traded fund offering broad exposure to the High-Yield/Junk Bond ETFs category of the market.
In Article Trend: Somewhat-Bullish
April 10, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree U.S. High Yield Corporate Bond ETF ( WFHY ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (10:00) / "Benzinga" (by Globe Newswire)
Medicines360 Appoints Erica Rogers to Board of Directors
SAN FRANCISCO, April 10, 2024 ( GLOBE NEWSWIRE ) -- Medicines360, a global mission-driven women's health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024.
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:24) / "Zacks Commentary" (by Zacks Equity Research)
Why HCA Healthcare ( HCA ) is a Smart Addition to Your Portfolio
HCA Healthcare (HCA) remains well-poised for growth on growing patient volumes, buyouts, effective telehealth services and a notable financial stand.
In Article Trend: Bullish
April 8, 2024 (22:15) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But Organon ( OGN ) Gained Today
In the most recent trading session, Organon (OGN) closed at $18.16, indicating a +1.68% shift from the previous trading day.
In Article Trend: Neutral
April 5, 2024 (07:00) / "The Economist" (by The Economist)
Would you risk a breakdown to cure baldness?
Ben's barber was the first person to notice he was losing his hair. After that it wasn't long until everyone else noticed too. He was a postgraduate student in his 20s, tall and attractive in an equine way. But soon his receding hairline became an obsession.
In Article Trend: Somewhat-Bearish
April 4, 2024 (17:37) / "Zacks Commentary" (by Zacks Equity Research)
Encompass Health ( EHC ) Plans a 50-Bed Facility to Serve Texas
Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.
In Article Trend: Somewhat-Bullish
March 21, 2024 (12:00) / "GlobeNewswire" (by Inc.)
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
SAN DIEGO, March 21, 2024 ( GLOBE NEWSWIRE ) -- Daré Bioscience, Inc. ( NASDAQ: DARE ) , a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (10:23) / "Business Standard" (by Capital Market)
Barometers end with small gains; oil & gas shares advance
Barometers end with small gains. oil & gas shares advance Business Standard ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (04:22) / "Business Standard" (by Capital Market)
Auro Pharma rises on USFDA nod for nasal spray
Aurobindo Pharma added 1.28% to Rs 1,002.05 after the drug maker received final approval from the US Food & Drug Administration ( USFDA ) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray.
In Article Trend: Neutral
March 20, 2024 (04:03) / "Business Standard" (by Capital Market)
Indices drift higher in early trade; breadth strong
Indices drift higher in early trade. breadth strong Business Standard ...
In Article Trend: Somewhat-Bullish
March 20, 2024 (03:57) / "Money Control"
Aurobindo Pharma share up nearly 2% on USFDA approval for nasal spray
The share touched a 52-week high of Rs 1,177 on January 30, 2024 and a 52-week low of Rs 466 on March 21, 2023.
In Article Trend: Neutral
March 20, 2024 (03:22) / "Business Standard" (by Capital Market)
TCS, Aurobindo Pharma, IFCI, KIOCL in spotlight
Tata Consultancy Services ( TCS ) : TCS announced that Central Bank, a leading Midwest regional bank, will use TCS BaNCS to update its core technology infrastructure, drive innovation, and strengthen customer relationships.
In Article Trend: Somewhat-Bullish
March 19, 2024 (16:52) / "Zacks Commentary" (by Zacks Equity Research)
UnitedHealth ( UNH ) to Roll Out Medical Claims Software Soon
UnitedHealth (UNH) assists care providers with more than $2 billion through several initiatives to mitigate the cash flow crunch arising from the cyberattack.
In Article Trend: Neutral
March 18, 2024 (13:58) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Centene ( CNC ) Stock for Now
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
In Article Trend: Somewhat-Bullish
March 14, 2024 (21:00) / "Zacks Commentary" (by Shaun Pruitt)
Markets Dip but it's Time to Buy These Low-Risk High-Income Stocks
Now may be an ideal time to buy these lower-risk, high-income stocks especially as markets start to digest hot inflationary data.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Envista ( NVST ) Faces Macroeconomic Challenges, FX Headwind
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
In Article Trend: Somewhat-Bullish
March 13, 2024 (14:13) / "Zacks Commentary" (by Zacks Equity Research)
Centene ( CNC ) , Pearl Health Unite to Enhance Value-Based Care
Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:24) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Medtronic ( NYSE:MDT ) , Amgen ( NASDAQ:AMGN )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
March 12, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Cigna ( CI ) Stock to Your Portfolio
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, value enhancing initiatives and a positive 2024 outlook poise it well for growth.
In Article Trend: Somewhat-Bullish
March 11, 2024 (16:22) / "Zacks Commentary" (by Zacks Equity Research)
Teladoc Health ( TDOC ) Unveils Solution to Ease Weight Loss
Teladoc Health (TDOC) expands weight management capabilities by coming up with a tailored solution that aims to reduce obesity-related medical care expenses for members.
In Article Trend: Bullish
March 11, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Organon Shows Rising Price Performance With Jump To 81 RS Rating
On Monday, Organon ( OGN ) hit an important technical milestone, with its Relative Strength ( RS ) Rating climbing into the 80-plus percentile with an improvement to 81, an increase from 76 the day before.
In Article Trend: Somewhat-Bullish
March 9, 2024 (15:05) / "Benzinga" (by Globe Newswire)
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology ( AAD ) Annual Meeting
INCHEON, Korea, March 09, 2024 ( GLOBE NEWSWIRE ) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio - SB5, a biosimilar to Humira1 ( adalimumab ) , and SB17, a proposed biosimilar to Stelara2 ( ustekinumab ) - at the 2024 American Academy of Dermatology ( ...
In Article Trend: Neutral
March 8, 2024 (14:01) / "Canada Newswire" (by Organon Canada Inc.)
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender ... Canada ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (06:00) / "GlobeNewswire" (by Mithra Pharmaceuticals)
Mithra reports full year 2023 financial results
• Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively impacted by exceptional upfront cash payments from partnerships. • Product sales were EUR 18.7 million, up +19.3% vs EUR 15.7 million in 2022. • ESTELLE® product sales reached EUR 10.4 million in ...
In Article Trend: Somewhat-Bullish
February 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stock Upgrades: Organon Shows Rising Relative Strength
In a welcome move, Organon ( OGN ) saw its Relative Strength Rating rise from 66 to 71 on Wednesday. X When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.
In Article Trend: Bullish
February 27, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
Cencora, Inc. ( COR ) Hit a 52 Week High, Can the Run Continue?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
In Article Trend: Somewhat-Bullish
February 26, 2024 (15:56) / "Benzinga" (by Vandana Singh)
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety - Organon ( NYSE:OGN )
The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair ( montelukast ) .
In Article Trend: Somewhat-Bearish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website